Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.
Abstract
Publication Date:
2019
Iris type:
1.5 Abstract in rivista
List of contributors:
Siena, S; Sartore-Bianchi, A; Personeni, N; Pietrantonio, F; Germano, G; Amatu, A; Bonoldi, E; Valtorta, E; Barault, L; Di Nicolantonio, F; Siravegna, G; Crisafulli, G; Rimassa, L; De Braud, Fg; Santoro, A; Lazzari, L; Luraghi, P; Amirouchene-Angelozzi, N; Bardelli, A; Marsoni, S
Published in: